Triple
T1137481
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Ladin language |
E23172
|
entity |
| Predicate | hasDialect |
P4251
|
FINISHED |
| Object |
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
|
E130780
|
NE FINISHED |
How this triple was built (4 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Anpezan | Statement: [Ladin language, hasDialect, Anpezan]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Anpezan Context triple: [Ladin language, hasDialect, Anpezan]
-
A.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
B.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
-
C.
Versonnex
Versonnex is a small commune in the Ain department of eastern France, located near the Swiss border in the Pays de Gex region.
-
D.
Plegridy
Plegridy is a pegylated interferon beta-1a medication used to treat relapsing forms of multiple sclerosis.
-
E.
Denesuline
Denesuline are a First Nations people of the larger Dene cultural and linguistic group, traditionally inhabiting subarctic regions of northern Canada.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Anpezan Triple: [Ladin language, hasDialect, Anpezan]
Generated description
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Anpezan Target entity description: Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
A.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
B.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
-
C.
Versonnex
Versonnex is a small commune in the Ain department of eastern France, located near the Swiss border in the Pays de Gex region.
-
D.
Plegridy
Plegridy is a pegylated interferon beta-1a medication used to treat relapsing forms of multiple sclerosis.
-
E.
Denesuline
Denesuline are a First Nations people of the larger Dene cultural and linguistic group, traditionally inhabiting subarctic regions of northern Canada.
- F. None of above. chosen
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69a493ec75988190b63a11bafaec29b4 |
completed | March 1, 2026, 7:30 p.m. |
| NER | Named-entity recognition | batch_69a4bc2450c481909b9264e170070326 |
completed | March 1, 2026, 10:22 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69ac59ae5f20819093f8acc3ba7a6638 |
completed | March 7, 2026, 5 p.m. |
| NEDg | Description generation | batch_69ac5b5e2c688190a7d4998a3ed0f443 |
completed | March 7, 2026, 5:07 p.m. |
| NED2 | Entity disambiguation (via description) | batch_69ac5bb6e78c8190a34ecbc246f72ff6 |
completed | March 7, 2026, 5:09 p.m. |
Created at: March 1, 2026, 7:44 p.m.